Biomarkers for prostate cancer.
Novel biomarkers for prostate cancer (PCa) are currently being assessed for utility in PCa diagnosis. This article aims to provide concise information on the current findings that impact prostate cancer research. Results of enzyme-linked immunosorbent assays (ELISA) for single biomarkers, quantitative polymerase chain reaction (PCR)-based assays for DNA/RNA markers will be reviewed in addition to high-throughput proteomic profiling of PCa specimens. The advantages/disadvantages of tissue, blood, urine or seminal plasma as sources for potential biomarkers are discussed emphasizing the consequences for PCa diagnosis. In summary, the majority of promising marker candidates available today needs further validation. Some of the identified markers have the potential to yield novel prognostic tools for PCa, provide novel insights into its pathophysiology, and contribute to the establishment of novel treatment strategies.
Schiffer
Eric
E
Mosaiques Diagnostics and Therapeutics AG, Mellendorfer Str. 7-9, 30625 Hannover, Germany. schiffer@mosaiques-diagnostics.com
D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood / Q000652:urine; D045744:Cell Line, Tumor / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D052138:Genes, Neoplasm; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000378:metabolism; D016133:Polymerase Chain Reaction; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D040901:Proteomics; D012661:Semen / Q000378:metabolism
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins
Cancer Res. 1996 Jan 1;56(1):218-22
8548767
Cancer Res. 2005 May 15;65(10):4097-100
15899799
Mass Spectrom Rev. 2005 Nov-Dec;24(6):959-77
15747373
N Engl J Med. 1987 Oct 8;317(15):909-16
2442609
Cancer Res. 2004 Sep 1;64(17):5929-33
15342369
Cancer Cell. 2005 Nov;8(5):393-406
16286247
Neoplasia. 2006 Jan;8(1):59-68
16533427
Lancet Oncol. 2006 Mar;7(3):230-40
16510332
N Engl J Med. 2004 May 27;350(22):2239-46
15163773
Genome Biol. 2006;7(5):R40
16709260
J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9
12122098
Clin Cancer Res. 2003 Jul;9(7):2673-7
12855646
J Urol. 2004 Oct;172(4 Pt 1):1501-3
15371879
Diagn Mol Pathol. 1997 Aug;6(4):192-8
9360840
Kidney Int. 2004 Jan;65(1):323-32
14675066
Cancer Res. 1999 Dec 1;59(23):5975-9
10606244
Urol Oncol. 2004 Jul-Aug;22(4):329-36
15283892
Prostate. 2006 Jul 1;66(10):1029-36
16598740
Proteomics Clin Appl. 2007 Feb;1(2):148-56
21136664
Electrophoresis. 2005 Jul;26(14):2797-808
15981297
Clin Chem. 2005 Dec;51(12):2236-44
16239339
J Urol. 2003 Mar;169(3):1138-42
12576869
Urologe A. 2007 Jul;46(7):733-9
17318473
Eur Urol. 2004 Aug;46(2):271-2
15245824
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
16514137
Lancet. 2003 Mar 8;361(9360):859-64
12642065
Science. 1996 Nov 8;274(5289):998-1001
8875945
J Urol. 2005 Jan;173(1):73-8
15592032
Cancer Res. 2002 Jul 1;62(13):3609-14
12097261
Clin Chim Acta. 1986 Dec 30;161(3):335-9
2433078
Bioinformatics. 2004 Mar 22;20(5):777-85
14751995
Radiol Clin North Am. 2000 Jan;38(1):49-58
10664666
Prostate. 2006 Sep 1;66(12):1235-44
16705742
Eur J Surg Oncol. 2000 Feb;26(1):44-9
10718179
J Natl Cancer Inst. 2005 Feb 16;97(4):307-9
15713966
Proteomics. 2006 Jan;6(2):697-708
16252305
Nature. 2004 Jun 3;429(6991):496-7
15175721
J Urol. 2005 Aug;174(2):514-8
16006883
Clin Chem. 2005 Aug;51(8):1432-42
15961548
Pathobiology. 2000;68(4-5):209-14
11279348
J Clin Oncol. 2005 Sep 20;23(27):6569-75
16170165
Urology. 2002 Dec;60(6):1131-5
12475696
N Engl J Med. 2003 Jul 17;349(3):215-24
12824459
Urology. 2001 Sep;58(3):335-8
11549474
Urology. 2004 Oct;64(4):821-5
15491741
Clin Biochem. 2005 Jun;38(6):558-71
15885237
Urology. 2004 Dec;64(6):1238-43
15596215
Cancer Res. 2002 May 1;62(9):2695-8
11980670
Cancer Lett. 1988 Dec 1;43(1-2):9-14
2462465
Cancer Res. 2000 Nov 1;60(21):5941-5
11085508
Rapid Commun Mass Spectrom. 2004;18(19):2365-6
15384161